Clinical characteristics and outcome of COVID-19 patients with Parkinson’s disease: a hospital-based case–control study in Shanghai, China

Frontiers in Aging Neuroscience

Aging Neuroscience

Xin Nie¹  Wenyan Kang²  Xiaolei Shen³  Wei Chen³  Jianren Liu³  Li Wu³  Jun Shen³  Ping Wang³  Yuhan Jiang³ 

[1] Biostatistics Office of Clinical Research Unit, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital), Shanghai, Hainan, China;Department of Neurology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;

关键词: COVID-19;    Omicron;    Parkinson’s disease;    clinical characteristics;    outcome;   

DOI  :  10.3389/fnagi.2023.1138418

 received in 2023-01-06, accepted in 2023-04-19,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundClinical manifestations of Parkinson’s disease (PD) after Corona Virus Disease 2019 (COVID-19) infection are poorly investigated.ObjectiveWe aimed to explore the clinical features and outcomes of hospitalized PD patients with COVID-19.MethodsA total of 48 PD patients and 96 age-and sex-matched non-PD patients were included. Demographics, clinical characteristics and outcomes were compared between two groups.ResultsPD patients with COVID-19 were elderly (76.69 ± 9.21 years) with advanced stage (H-Y stage 3–5 as 65.3%). They had less clinical symptoms (nasal obstruction, etc.), more proportions of severe/critical COVID-19 clinical classification (22.9 vs. 1.0%, p < 0.001), receiving oxygen (29.2 vs. 11.5%, p = 0.011), antibiotics (39.6 vs. 21.9%, p = 0.031) therapies, as well as longer hospitalization duration (11.39 vs. 8.32, p = 0.001) and higher mortality (8.3% vs. 1.0%, p = 0.001) relative to those without PD. Laboratory results showed that the PD group had higher white blood cell counts (6.29 vs. 5.16*109, p = 0.001), neutrophil-to-lymphocyte ratio (3.14 vs. 2.11, p < 0.001) and C-reactive protein level (12.34 vs. 3.19, p < 0.001).ConclusionPD patients with COVID-19 have insidious clinical manifestation, elevated proinflammatory markers and are prone to the development of severe/critical condition, contributing to a relatively poor prognosis. Early identification and active treatment of COVID-19 are pivotal to advanced PD patients during the pandemic.

【 授权许可】

Unknown   
Copyright © 2023 Wu, Shen, Jiang, Shen, Wang, Nie, Kang, Liu and Chen.